# An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

> **NCT02211222** · — · APPROVED_FOR_MARKETING · sponsor: **Eisai Inc.**

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02211222
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** 2015-08
- **Final completion:** 2015-06
- **Target enrollment:** — (—)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211222, "An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02211222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*